Abstract: A controller includes a body and a surrounding part. The body has a control area for sending a control signal according to a movement of a thumb of a user. The surrounding part is connected to the body and used to surround and be fixed to a proximal phalange of an index finger of the user. The body is away from a joint between the proximal phalange and a metacarpal bone of the user.

Abstract: The embodiments of the disclosure provide a method for hand tracking. The method includes: obtaining, through a head-mounted device, a first image of a hand; determining, through the processor, a first pose of a first part of the hand based on the first image; obtaining, through a hand-held device, a second image of the hand; determining, through the processor, a second pose of a second part of the hand based on the second image, wherein the first part and the second part complementarily form an entirety of the hand; and determining, through the processor, a gesture of the hand based on the first pose and the second pose.

Abstract: A method against coronavirus infection includes administering to a subject in need thereof a pharmaceutical composition containing a water-extracted product of Melastoma malabathricum root.

Abstract: A handheld controller is adapted to control an electronic device. The handheld controller includes a first body, a second body, and a connecting portion. The first body is adapted to be held by a user's hand. The second body is connected to the first body through the connecting portion. The connecting portion is adapted to be clamped between user's fingers. A distance between the first body and at least a portion of the second body is variable.

Abstract: A backside illuminated image sensor structure including a pixel structure is provided. The pixel structure includes a substrate, a light sensing device, and at least one light pipe structure. The substrate includes a first surface and a second surface opposite to each other. The second surface has at least one recess. The light sensing device is located in the substrate. The light sensing device is adjacent to the first surface. The light pipe structure is located in the substrate. The light pipe structure is located directly above the light sensing device.

Abstract: A handheld controller is adapted to control an electronic device. The handheld controller includes a first body, a second body, and a connecting portion. The first body is adapted to be held by a user's hand. The second body is connected to the first body through the connecting portion. The connecting portion is adapted to be clamped between user's fingers. A distance between the first body and at least a portion of the second body is variable.

Abstract: Methods and systems for controlling an output voltage of a resonant converter during a light load condition. One such method includes generating a normalised conduction time of the resonant converter that varies inversely with a switching frequency of the resonant converter by continuing to operate the resonant converter in a Pulse Frequency Modulation mode at a low switching frequency that is similar to the resonant frequency. The method also includes controlling a power level delivered to a secondary winding of a transformer positioned between a resonant tank and an output rectifier of the resonant converter by regulating the normalised conduction time, where the delivered power level is variable based on load conditions. The method further includes generating an output voltage using the output rectifier wherein the magnitude of the output voltage corresponds to the power level delivered to the secondary winding.

Abstract: Methods and systems for controlling an output voltage of a resonant converter during a light load condition. One such method includes generating a normalised conduction time of the resonant converter that varies inversely with a switching frequency of the resonant converter by continuing to operate the resonant converter in a Pulse Frequency Modulation mode at a low switching frequency that is similar to the resonant frequency. The method also includes controlling a power level delivered to a secondary winding of a transformer positioned between a resonant tank and an output rectifier of the resonant converter by regulating the normalised conduction time, where the delivered power level is variable based on load conditions. The method further includes generating an output voltage using the output rectifier wherein the magnitude of the output voltage corresponds to the power level delivered to the secondary winding.

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

Abstract: Methods and systems for balancing output currents of parallel connected resonant converters are disclosed. One such method includes matching switching frequencies for a pair of resonant converters. The method also includes carrying AC output currents of resonant tanks of each of the resonant converters through a current controlled voltage source that is coupled to each of the resonant converters of the pair of resonant converters at an AC side of each of the resonant converters of the pair of resonant converters. The method further includes inducing, for the pair of resonant converters, a voltage that is proportional to a difference in the AC currents carried through the current controlled voltage source by passing the AC currents through the current controlled voltage source. The induced voltage is oriented to oppose the greater of the AC currents and to increase the smaller of the AC currents.

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

Abstract: Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

Abstract: Disclosed herein are compounds, compositions and methods for treating tumors, particularly tumors that metastasize, via inhibiting tumor cells-induced platelet aggregation. The compound of the present disclosure has the formula (I), wherein, n is 2 or 3.

Abstract: Contemplated compositions and methods are drawn to biomarkers and methods related to treatment of neoplastic disease with Hec1 inhibitor. Gene status and/or expression levels of Hec1(HEC), Rb(RB1), and/or p53 (TP53) may be useful as biomarkers for sensitivity to treatment with a Hec1 inhibitor. In addition, Hec 1 inhibitors may show synergistic effects when used in conjunction with cytotoxic drugs.

Abstract: Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

Abstract: Disclosed herein are compounds, compositions and methods for treating tumors, particularly tumors that metastasize, via inhibiting tumor cells-induced platelet aggregation. The compound of the present disclosure has the formula (I), wherein, n is 2 or 3.

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.